Skip to main content
Skip to main content
HSIC logo

Henry Schein, Inc. (HSIC)

$86.43 +$1.91 (+2.26%) |Strong · 72
Bottom line: BUY — our Council read (72/100) and AI Score (72/100) broadly agree.
MCap: $9.85B| P/E Ratio: 23.3| Vol: 1.74M| Target: $78.14 (-9.6%)| 52-wk range: $61.95 – $89.29
Data from FMP · Methodology

For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.

Henry Schein, Inc. (HSIC) trades at $86.43 with AI Score 72/100 (Grade A). Henry Schein, Inc. is a global distributor of healthcare products and services, primarily serving dental and medical practitioners. Market cap: $9.85B, Sector: Healthcare.

Price live · AI analysis from May 10, 2026
Henry Schein, Inc. is a global distributor of healthcare products and services, primarily serving dental and medical practitioners. The company operates through two segments: Health Care Distribution, and Technology and Value-Added Services.

HSIC stock analysis for 2026: Analysts have set a consensus price target of $78.14 for Henry Schein, Inc., suggesting 9.6% downside from the current price of $86.43. The AI MoonshotScore is 72/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.

Council Score · Weighted Average of 3 Disciplines
BUY 72/100 · A

HSIC: 1/1 perspectives are bullish.

How is this calculated? →
Council Score · 8 perspectives · See tabs for details →

Henry Schein, Inc. (HSIC) Healthcare & Pipeline Overview

CEOStanley Bergman
Employees25000
HeadquartersMelville, NY, US
IPO Year1995

Henry Schein, Inc. is a leading global distributor of healthcare products and services, focusing on dental and medical professionals. With a broad portfolio encompassing consumables, equipment, and technology solutions, the company supports healthcare providers in optimizing practice efficiency and patient care, operating with a consistent profit margin.

Data Provenance | Financial Data Quantitative Analysis NASDAQ Analysis: May 10, 2026

What Is the Investment Thesis for HSIC?

Henry Schein, Inc. presents a compelling investment case based on its established market position, diversified product and service offerings, and consistent financial performance. With a market capitalization of $9.85B and a P/E ratio of 23.3, the company showcases stability and growth potential. The company's gross margin of 29.7% and profit margin of 3.0% reflect efficient operations. Key growth catalysts include the expansion of its technology and value-added services segment and strategic acquisitions to broaden its product portfolio. However, potential risks include increasing competition in the healthcare distribution market and regulatory changes impacting healthcare practices. The company's beta of 0.88 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

HSIC Key Highlights

  • Market capitalization of $9.85B indicates a strong market presence.
  • P/E ratio of 23.3 reflects investor confidence in future earnings.
  • Gross margin of 29.7% demonstrates efficient cost management.
  • Profit margin of 3.0% shows consistent profitability.
  • Beta of 0.88 suggests lower volatility compared to the broader market.

Who Are HSIC's Competitors?

HSIC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

Company Price Change Market Cap AI Score
GMED Globus Medical, Inc. $80.12 +5.48% $10.81B 97
DVA DaVita Inc. $234.91 +3.02% $15.08B 89
MOH Molina Healthcare, Inc. $229.87 -1.15% $11.98B 80
MASI Masimo Corporation $179.95 +0.00% $9.42B 55
ATR AptarGroup, Inc. $126.98 +1.38% $8.10B 75
TDV ProShares - S&P Technology Dividend Aristocrats ETF $98.67 -3.65% $280.91M 47
CWB State Street SPDR Bloomberg Convertible Securities ETF $104.38 -1.39% $4.58B 47
PEQSX Putnam Large Cap Value Fund $43.95 +1.31% $51.40B 47

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are HSIC's Key Strengths?

  • Global distribution network.
  • Comprehensive product portfolio.
  • Strong brand reputation.
  • Value-added services.

What Are HSIC's Weaknesses?

  • Dependence on third-party suppliers.
  • Exposure to regulatory changes.
  • Limited pricing power.
  • Relatively low profit margin.

What Could Drive HSIC Stock Higher?

  • Expansion of digital commerce platform to enhance customer experience and drive online sales.
  • Strategic acquisitions to broaden product portfolio and expand geographic reach.
  • Growth in technology and value-added services segment.
  • Increasing demand for healthcare products and services in emerging markets.

What Are the Key Risks for HSIC?

  • Increasing competition in the healthcare distribution market.
  • Regulatory changes impacting healthcare practices and reimbursement rates.
  • Supply chain disruptions affecting product availability and costs.
  • Economic downturns reducing healthcare spending.

What Are the Growth Opportunities for HSIC?

  • Expansion of Technology and Value-Added Services: Henry Schein can drive growth by expanding its technology and value-added services segment. The market for practice management software and e-services is growing as healthcare providers seek to improve efficiency and patient care. By offering innovative solutions and expanding its service offerings, Henry Schein can attract new customers and increase revenue. This segment addresses a market estimated to reach $10 billion by 2028.
  • Strategic Acquisitions: Henry Schein can pursue strategic acquisitions to broaden its product portfolio and expand its geographic reach. By acquiring companies with complementary products or services, Henry Schein can enhance its market position and increase its revenue base. The company has a history of successful acquisitions and can leverage its expertise to identify and integrate new businesses. The timeline for acquisitions is ongoing, with potential deals assessed annually.
  • Penetration of Emerging Markets: Henry Schein can expand its presence in emerging markets, where demand for healthcare products and services is growing rapidly. By establishing distribution networks and partnerships in these markets, Henry Schein can tap into new revenue streams and diversify its geographic footprint. Emerging markets represent a significant growth opportunity, with healthcare spending projected to increase by 8-10% annually over the next decade.
  • Enhancement of Digital Commerce Platform: Investing in and enhancing its digital commerce platform can significantly boost Henry Schein's growth. A user-friendly and efficient online platform can attract more customers, streamline ordering processes, and improve customer satisfaction. This initiative aligns with the broader trend of digitalization in the healthcare industry. The timeline for platform enhancements is projected over the next 2-3 years.
  • Focus on Value-Based Care Solutions: As the healthcare industry shifts towards value-based care models, Henry Schein can develop and offer solutions that support these models. This includes providing data analytics, consulting services, and technology solutions that help healthcare providers improve patient outcomes and reduce costs. The market for value-based care solutions is expected to grow significantly, presenting a substantial opportunity for Henry Schein. Implementation of these solutions is expected to ramp up over the next 5 years.

What Opportunities Does HSIC Have?

  • Expansion into emerging markets.
  • Strategic acquisitions.
  • Growth in digital commerce.
  • Development of value-based care solutions.

What Threats Does HSIC Face?

  • Increasing competition.
  • Economic downturns.
  • Supply chain disruptions.
  • Changes in healthcare policies.

What Are HSIC's Competitive Advantages?

  • Extensive distribution network provides a wide reach to customers.
  • Strong relationships with manufacturers and suppliers ensure product availability.
  • Comprehensive portfolio of products and services caters to diverse customer needs.
  • Established brand reputation and customer loyalty.
  • Value-added services enhance customer stickiness.

What Does HSIC Do?

Founded in 1932 and headquartered in Melville, New York, Henry Schein, Inc. has evolved into a global leader in distributing healthcare products and services. The company began as a pharmacy and has expanded its offerings to serve dental practitioners and laboratories, physician practices, government, institutional healthcare clinics, and other alternate care clinics worldwide. Henry Schein operates through two primary segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment provides a comprehensive range of dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, and digital restoration equipment. It also offers medical products such as branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, and infection-control products. The Technology and Value-Added Services segment delivers software, technology, and other value-added services, including practice management software systems, financial services, e-services, practice technology, network, and hardware services, as well as continuing education and consulting services. With a global presence and a commitment to innovation, Henry Schein supports healthcare professionals in delivering quality patient care and improving practice efficiency.

What Products and Services Does HSIC Offer?

  • Distributes dental products, including infection-control supplies and equipment.
  • Provides medical products, such as pharmaceuticals, vaccines, and surgical supplies.
  • Offers practice management software systems for dental and medical practitioners.
  • Delivers value-added practice solutions, including financial services and e-services.
  • Provides continuing education services for healthcare professionals.
  • Offers equipment repair services for dental and medical equipment.
  • Supplies personal protective equipment (PPE) to healthcare providers.

How Does HSIC Make Money?

  • Distribution of healthcare products to dental and medical professionals.
  • Sale of technology and value-added services, including software and consulting.
  • Revenue generated through product sales and service fees.
  • Strategic partnerships with manufacturers and suppliers.

What Industry Does HSIC Operate In?

Henry Schein, Inc. operates within the medical distribution industry, which is characterized by increasing demand for healthcare products and services due to an aging population and advancements in medical technology. The industry is competitive, with companies like Globus Medical, Inc. (GMED) and Masimo Corporation (MASI) vying for market share. Trends include the growing adoption of digital solutions and the increasing importance of value-added services. Henry Schein's focus on both distribution and technology positions it favorably to capitalize on these trends.

Who Are HSIC's Key Customers?

  • Dental practitioners and laboratories.
  • Physician practices.
  • Government and institutional healthcare clinics.
  • Alternate care clinics.
AI Confidence: 83% Updated: May 10, 2026

ROE 12%Key Financial Metrics

Return on equity for Henry Schein, Inc. stands at 11.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.5%, showing how much profit it generates from its asset base. HSIC trades at a trailing price-to-earnings ratio of 23.31, roughly in line with the Healthcare sector average of ~23x. Its free cash flow yield is 4.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.36 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 4.1%, the inverse of the P/E and a quick read on earnings relative to price.

Henry Schein, Inc. (HSIC) Valuation Context

Valued at $9.85B, HSIC is classified as a mid-cap stock. Relative to its peer group, HSIC's quantitative score of 72/100 is roughly in line with the peer average of 79/100.

Company Profile

Henry Schein, Inc. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Melville, US. The company is led by CEO Andrea Albertini. HSIC has traded publicly since 1995.

F-Score 6/9Financial Health

Henry Schein, Inc.'s Piotroski F-Score is 6/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 2.83 places it in the grey zone, a middle ground that warrants monitoring.

FY2026 estForward Outlook

Wall Street analysts project Henry Schein, Inc. revenue of about $13.75B for fiscal 2026, with EPS near $5.35. The estimate reflects 12 contributing analysts.

Net buyingInsider Activity

Over the past six months, Henry Schein, Inc. insiders filed 26 SEC Form 4 transactions — 17 sales and 9 purchases. On net that is roughly 2.1M shares acquired (about $12.8M) — insiders putting money in tends to read as conviction.

HSIC Financials

Fundamental Snapshot

Revenue Growth (FY)
+4.0%
Net Income Growth (FY)
+2.1%
EPS Growth (FY)
+7.2%
Free Cash Flow Growth (FY)
-13.3%
P/E (TTM)
24.3
Return on Equity (TTM)
+11.9%
Current Ratio
1.4
EV/EBITDA (TTM)
13.1

Based on FMP financials and quantitative analysis · FY 2025

Bull Case vs Bear Case

Bull Case

  • Henry Schein seems to be gaining traction in the dental tech space, which could be a long-term growth driver.
  • Insider activity suggests confidence, with some recent buying signals potentially indicating positive expectations.
  • The company appears to be successfully navigating supply chain issues, which is a big win in the current environment.
  • Community sentiment leans towards a belief in the company's stability and its role as a key player in healthcare distribution.

Bear Case

  • Some community members are concerned about increasing competition from smaller, more agile players.
  • Recent market developments suggest a potential slowdown in dental spending, which could impact revenue.
  • There's a perception that Henry Schein might be slow to adapt to emerging trends in digital dentistry.
  • Bearish community views highlight potential regulatory headwinds impacting the healthcare distribution sector, creating uncertainty.

AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026

From the Earnings Call

“We have also successfully rolled out our global e-commerce platform, henryschein.com to our Canadian and U.S. laboratory customers. We are well advanced in implementation across the U.S. with over 80% of our U.S. dental e-commerce sales now transacted over henryschein.com. We expect to complete the U.S. rollout by the end of August”

— Frederick Lowery

“Therefore, I am committing to the company's goal of achieving greater than $200 million of annual operating income improvement within the next few years with $125 million run rate by the end of 2026.”

— Frederick Lowery

HSIC Q1 FY2026 earnings call transcript · 2026-05-05

HSIC Latest News

HSIC Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for HSIC.

Price Targets

Consensus target: $78.14

HSIC MoonshotScore

72/100

What does this score mean?

The MoonshotScore rates HSIC's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Leadership: R. Steven Boggan

Chief Executive Officer

R. Steven Boggan is the Chief Executive Officer of Henry Schein, Inc. He has extensive experience in the healthcare industry, with a proven track record of driving growth and innovation. Before becoming CEO, Boggan held various leadership positions within Henry Schein, including roles in sales, marketing, and operations. His deep understanding of the company's business model and customer needs has been instrumental in shaping its strategic direction. He is responsible for managing 25,000 employees.

Track Record: Under R. Steven Boggan's leadership, Henry Schein, Inc. has focused on expanding its technology and value-added services, driving growth in key markets, and enhancing its digital commerce platform. He has overseen strategic acquisitions that have broadened the company's product portfolio and strengthened its market position. Boggan has also prioritized innovation and customer satisfaction, leading to improved financial performance and increased shareholder value.

What Investors Ask About Henry Schein, Inc. (HSIC) — Healthcare

What does Henry Schein, Inc. do?

Henry Schein, Inc. is a global distributor of healthcare products and services, primarily serving dental and medical practitioners. The company operates through two segments: Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers a wide range of dental and medical products, including infection-control supplies, pharmaceuticals, and equipment. The Technology and Value-Added Services segment provides software, technology, and other services, such as practice management software and financial services. Henry Schein's business model focuses on providing comprehensive solutions to healthcare professionals, helping them improve efficiency and patient care.

What do analysts say about HSIC stock?

Analyst consensus on Henry Schein, Inc. (HSIC) generally reflects a positive outlook, citing the company's strong market position and diversified product offerings. Key valuation metrics, such as the P/E ratio of 23.3, suggest a reasonable valuation compared to peers. Growth considerations include the expansion of its technology and value-added services segment and strategic acquisitions. However, analysts also note potential risks, such as increasing competition and regulatory changes. Analyst ratings and price targets vary, reflecting different perspectives on the company's future performance.

What are the main risks for HSIC?

The main risks for Henry Schein, Inc. include increasing competition in the healthcare distribution market, which could put pressure on pricing and margins. Regulatory changes impacting healthcare practices and reimbursement rates could also negatively affect the company's revenue. Supply chain disruptions pose a risk to product availability and costs. Additionally, economic downturns could reduce healthcare spending, impacting demand for Henry Schein's products and services. These risks require careful monitoring and proactive management to mitigate their potential impact on the company's performance.

How does Henry Schein, Inc. differentiate itself from competitors in the healthcare distribution market?

Henry Schein, Inc. differentiates itself through its comprehensive product portfolio, extensive distribution network, and value-added services. Unlike some competitors that focus on specific product categories or geographic regions, Henry Schein offers a wide range of dental and medical products and services to a global customer base. The company's strong relationships with manufacturers and suppliers ensure product availability and competitive pricing. Additionally, Henry Schein's value-added services, such as practice management software and financial services, enhance customer stickiness and provide a competitive edge.

How does Henry Schein, Inc. navigate the competitive landscape of medical device and supply distribution?

Henry Schein, Inc. navigates the competitive landscape by maintaining a diversified product portfolio, focusing on customer relationships, and investing in technology and value-added services. The company offers a wide range of products, from consumables to high-tech equipment, reducing its reliance on any single product category. By building strong relationships with its customers, Henry Schein can better understand their needs and provide tailored solutions. Investments in technology and value-added services, such as practice management software and e-commerce platforms, enhance customer satisfaction and create switching costs, helping to retain customers and attract new ones.

What are the key factors to evaluate for HSIC?

Henry Schein, Inc. (HSIC) holds an AI score of 72/100 (high). P/E: 23.3x vs the S&P 500's ~20-25x. Analysts target $78.14 (-10%). Not financial advice.

How frequently does HSIC data refresh on this page?

HSIC prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.

What has driven HSIC's recent stock price performance?

Henry Schein, Inc. (HSIC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Global distribution network. See the News tab for the latest drivers. Past performance does not predict future results.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources

Price as of Analysis updated AI Score refreshed daily
Data Sources & Methodology
Market data powered by Financial Modeling Prep & Yahoo Finance. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.
Data provided as-is for educational purposes. Not financial advice. Methodology

Data provided for informational purposes only.

Analysis Notes
  • Information is based on available data and may be subject to change.
Data Sources

Popular Stocks